(Q46643138)

English

Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database

scientific article published in April 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22376166

Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22376166

Domenico Motola

1

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22376166

4

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22376166

object named as

Carlo Piccinni

2

0 references

Elisabetta Poluzzi

object named as

Elisabetta Poluzzi

7

0 references

Giulio Marchesini

object named as

Giulio Marchesini

6

0 references

author name string

Chiara Biagi

3

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22376166

Anna Marra

5

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22376166

publication date

1 April 2012

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22376166

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22376166

35

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22376166

4

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22376166

315-323

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22376166

https://scigraph.springernature.com/pub.10.2165/11596510-000000000-00000

0 references

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

https://api.crossref.org/works/10.2165%2F11596510-000000000-00000

21 January 2018

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

1 reference

https://api.crossref.org/works/10.2165%2F11596510-000000000-00000

21 January 2018

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality

1 reference

https://api.crossref.org/works/10.2165%2F11596510-000000000-00000

21 January 2018

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.2165%2F11596510-000000000-00000

21 January 2018

Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD).

1 reference

https://api.crossref.org/works/10.2165%2F11596510-000000000-00000

21 January 2018

Risk of fractures with glitazones: a critical review of the evidence to date

1 reference

https://api.crossref.org/works/10.2165%2F11596510-000000000-00000

21 January 2018

Thiazolidinediones and fractures in men and women

1 reference

https://api.crossref.org/works/10.2165%2F11596510-000000000-00000

21 January 2018

The risk of fractures associated with thiazolidinediones: a self-controlled case-series study

1 reference

https://api.crossref.org/works/10.2165%2F11596510-000000000-00000

21 January 2018

Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.2165%2F11596510-000000000-00000

21 January 2018

Diabetic macular edema: correlations with available diabetes therapies--evidence across a qualitative review of published literature from MEDLINE and EMBASE.

1 reference

https://api.crossref.org/works/10.2165%2F11596510-000000000-00000

21 January 2018

Using MedDRA: implications for risk management

1 reference

https://api.crossref.org/works/10.2165%2F11596510-000000000-00000

21 January 2018

Use of measures of disproportionality in pharmacovigilance: three Dutch examples

1 reference

https://api.crossref.org/works/10.2165%2F11596510-000000000-00000

21 January 2018

Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database

1 reference

https://api.crossref.org/works/10.2165%2F11596510-000000000-00000

21 January 2018

Quantitative signal detection using spontaneous ADR reporting

1 reference

https://api.crossref.org/works/10.2165%2F11596510-000000000-00000

21 January 2018

The role of data mining in pharmacovigilance

1 reference

https://api.crossref.org/works/10.2165%2F11596510-000000000-00000

21 January 2018

Novel statistical tools for monitoring the safety of marketed drugs

1 reference

https://api.crossref.org/works/10.2165%2F11596510-000000000-00000

21 January 2018

Perspectives on the use of data mining in pharmaco-vigilance

1 reference

https://api.crossref.org/works/10.2165%2F11596510-000000000-00000

21 January 2018

Pharmacovigilance data mining with methods based on false discovery rates: a comparative simulation study

1 reference

https://api.crossref.org/works/10.2165%2F11596510-000000000-00000

21 January 2018

A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions.

1 reference

https://api.crossref.org/works/10.2165%2F11596510-000000000-00000

21 January 2018

Changes in glitazone use among office-based physicians in the U.S., 2003-2009.

1 reference

https://api.crossref.org/works/10.2165%2F11596510-000000000-00000

21 January 2018

Responding to an FDA warning--geographic variation in the use of rosiglitazone

1 reference

https://api.crossref.org/works/10.2165%2F11596510-000000000-00000

21 January 2018

Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting

1 reference

https://api.crossref.org/works/10.2165%2F11596510-000000000-00000

21 January 2018

Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase

1 reference

https://api.crossref.org/works/10.2165%2F11596510-000000000-00000

21 January 2018

Data mining in pharmacovigilance: the need for a balanced perspective

1 reference

https://api.crossref.org/works/10.2165%2F11596510-000000000-00000

21 January 2018

Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration

1 reference

https://api.crossref.org/works/10.2165%2F11596510-000000000-00000

21 January 2018

Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias

1 reference

https://api.crossref.org/works/10.2165%2F11596510-000000000-00000

21 January 2018

Data mining for signals in spontaneous reporting databases: proceed with caution

1 reference

https://api.crossref.org/works/10.2165%2F11596510-000000000-00000

21 January 2018

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.2165%2F11596510-000000000-00000

21 January 2018

Channeling bias in the interpretation of drug effects

1 reference

https://api.crossref.org/works/10.2165%2F11596510-000000000-00000

21 January 2018

'Extreme duplication' in the US FDA Adverse Events Reporting System database

1 reference

https://pubmed.ncbi.nlm.nih.gov/22376166

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems

1 reference

https://pubmed.ncbi.nlm.nih.gov/22376166

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/11596510-000000000-00000

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22376166

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22376166

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46643138&oldid=2123724235"